All these questions are related Pfizer Inc. and Biohaven Pharmaceutical Holding Company LTD acquisition. Please, use news and sec.gov1.Provide the basic details regarding the progression of the deal...

Question 1
According to the news, on 10th May 2022, Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced that they have entered into a definitive merger agreement. In accordance with the terms of agreement, Pfizer would pay $148.50 in cash for each share in Biohaven that it does not already hold. Pfizer is one of the Biohaven common shareholders who will also get 0.5 of a share in New Biohaven, a newly listed company that will continue to develop Biohaven's non-CGRP pipeline drugs. Both Biohaven's and Pfizer's boards of directors have unanimously endorsed the deal. Pfizer will pay the estimated $11.6 billion in cash that makes up the deal consideration. At closing, Pfizer will additionally pay Biohaven's third-party debt as well as the redemption of any shares of Biohaven's redeemable preferred stock that are still outstanding. In comparison to Biohaven's volume-weighted average sale price of $111.70 for the three months preceding to the announcement of the deal, the $148.50 cash consideration indicates a premium of around 33%.
Pfizer intends to use its available funds to fund the proposed deal. The agreement is contingent on...